UEGW 2024 Archives

On arrête l’adoucissant dans la nécrose pancréatique ! Jacob Hamm (Germany) - OP 229 PROTON PUMP INHIBITORS ARE ASSOCIATED WITH INCREASED LAMS OCCLUSION RATE AND A HIGHER NUMBER OF REQUIRED ENDOSCOPIC NECROSECTOMIES IN PATIENTS WITH PANCREATITIS,

Lutter contre la constipation avec de la gomme Sílvia Delgado-Aros (Switzerland) - RCT ASSESSING EFFECT OF 6-WEEK INTERVENTION WITH 10GR DAILY DOSE OF PARTIALLY HYDROLYZED GUAR GUM (PHGG) ON SPONTANEOUS BOWEL MOVEMENT FREQUENCY IN ADULTS WITH CHRONIC CONSTIPATION,

Le traitement d’Helicobacter Pylori : encore une histoire de vaccin ? Behnam Kalali (Germany) - A NOVEL MULTI-EPITOPE-BASED VACCINE AGAINST HELICOBACTER PYLORI; EVALUATION OF THE IMMUNOGENICITY AND PROTECTIVE EFFECT,

Rester à flot à la phase ultra précoce de la pancréatite aigüe Lucía Guilabert (Spain), Hospital General Universitario Dr. Balmis, Gastroenterology, Alicante. - IMPACT OF FLUID RESUSCITATION IN THE EMERGENCY DEPARTMENT ON CLINICAL OUTCOMES AND SAFETY IN ACUTE PANCREATITIS. A POST-HOC ANALYSIS OF THE WATERFALL CLINICAL TRIAL

Résection endoscopique d’adénocarcinome T1 à haut risque sur EBO : peut-on se passer de chirurgie ? Vincent Bos (Netherlands) - LOW RECURRENCE RATES AFTER ENDOSCOPIC RESECTION (R0) OF HIGH-RISK T1 ADENOCARCINOMA IN BARRETT’S ESOPHAGUS SUPPORT A STRICT ENDOSCOPIC SURVEILLANCE STRATEGY: PRELIMINARY RESULTS OF A PROSPECTIVE, INTERNATIONAL, MULTICENTER COHORT STUDY (PREFER),

Starwars X Dissection sous muqueuse : passer à une formation vitesse lumière ? Giorgio Carlino (France) - MP502 FEASIBILITY OF EXTENDED GASTRIC ENDOSCOPIC SUBMUCOSAL DISSECTION FOR LARGE LESIONS WITH A NOVEL FLEXIBLE ENDOSCOPIC ROBOTIC PLATFORM,

Le traitement d’Helicobacter Pylori : des réponses dans le suc gastrique ? Riccardo Vasapolli (Germany) - INNOVATIVE PROCEDURE FOR GENOTYPIC ANTIBIOTIC SUSCEPTIBILITY TESTING IN GASTRIC ASPIRATES FOLLOWING THE INTRAPROCEDURAL DETECTION OF H. PYLORI BY THE COMBINED ENDOSCOPY/ENDOFASTER METHOD,

Les anatomopathologistes au secours des gastro-entérologues pour prédire le risque de récidive de maladie de Crohn après une RIC Michiel T.J. Bak (Pays-Bas) - OP188 HISTOPATHOLOGICAL FEATURES IN THE RESECTION MARGINS FOR PREDICTION OF EARLY POSTOPERATIVE ENDOSCOPIC RECURRENCE IN CROHN’S DISEASE: A PROSPECTIVE, MULTICENTER COHORT STUDY

Le taux de détection des adénomes : une nouvelle donnée à prendre en compte pour la surveillance des patients post-polypectomie ? Nanette S. van Roermund (Netherlands) - RETHINKING POST-COLONOSCOPY COLORECTAL CANCER RISK: ENDOSCOPIST PERFORMANCE VERSUS PRESENCE OF HIGH-RISK POLYPS,

Cholangite sclérosante primitive et MICI : vers une cholangio-IRM systématique au diagnostic ? Mohamed Attauabi (Copenhagen) - SYSTEMATIC ASSESSMENT OF PRIMARY SCLEROSING CHOLANGITIS USING MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY IN NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE – A PROSPECTIVE POPULATION-BASED INCEPTION COHORT STUDY

IA de quoi réfléchir pour s’améliorer en endoscopie… Ejaz Hossain (United Kingdom), Queen Elizabeth Hospital, Gastroenetrology, London, United Kingdom - IMPROVING COLORECTAL POLYP OPTICAL DIAGNOSIS WITH COMPUTER AIDED CHARACTERIZATION: A REAL TIME COMPARISON WITH ENDOSCOPISTS AND ITS IMPACT AS A TRAINING TOOL

Encore plus d’extraits pancréatiques nécessaires dans le cancer du pancréas ! J.E. Domínguez Muñoz (Spain) - OPTIMAL DOSE OF PANCREATIC ENZYME REPLACEMENT THERAPY (PERT) FOR PANCREATIC EXOCRINE INSUFFICIENCY (PEI) IN DIFFERENT PANCREATIC DISEASES: RESULTS OF THE EUROPEAN PEI REGISTRY, ,

Détection des polypes coliques: vers une supériorité de l’IA sur l’humain? Rawen Kader (United Kingdom) - RANDOMIZED CONTROLLED TRIAL OF A CLOUD-BASED ARTIFICIAL INTELLIGENCE (AI) COMPUTER-AIDED DIAGNOSIS (CADX) SYSTEM IN NON-EXPERT ENDOSCOPISTS

EBO sans dysplasie : muter la surveillance selon TP 53 ? Pim Stougie (Netherlands) - IDENTIFYING PUTATIVE GENOMIC BIOMARKERS FOR RISK STRATIFICATION IN BARRETT’S ESOPHAGHUS PATIENTS WITH NORMAL HISTOLOGICAL FEATURES., , Prix "TOP ABSTRACT" remis par le comité UEG.

La berberine chinoise au secours du TFI ? Siqi Lu, Beijing, EFFICACY OF BERBERINE IN THE TREATMENT OF PATIENTS WITH IRRITABLE BOWEL SYNDROME COMORBID ANXIETY AND/OR DEPRESSION: A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL

A t-on défini le bon seuil de positivité du test FIT dans le dépistage du cancer colo-rectal ? Anna Forsberg (Suède) - OP164 COLONOSCOPY FINDINGS AFTER INCREASING FECAL IMMUNOCHEMICAL TEST (FIT) CUTOFF: CROSS-SECTIONAL ANALYSIS OF THE SCREESCO RANDOMIZED TRIAL

Faire une confiance aveugle dans l’IA en cholangioscopie ? Mariano Gonzalez-Haba (Spain) - OP099 ARTIFICIAL INTELLIGENCE FOR AUTOMATIC DIAGNOSIS AND PLEOMORPHIC MORPHOLOGIC CHARACTERIZATION OF MALIGNANT BILIARY STRICTURES USING DIGITAL CHOLANGIOSCOPY: A MULTICENTRIC TRANSATLANTIC STUDY,

L’ultratransformé, à (ultra) éviter même en rémission de maladie de Crohn ! Chen Sarbagili Shabat, Tel-Aviv, Israel - LB07- HIGH ULTRA-PROCESSED FOODS CONSUMPTION IS ASSOCIATED WITH CLINICAL EXACERBATION IN PATIENTS WITH CROHN'S DISEASE IN REMISSION - A PROSPECTIVE COHORT STUDY

Reprendre l’atézo-beva dans le CHC sur cirrhose CHILD B après décompensation, c’est possible ! Leonardo Stella (Italy) - LIVER DECOMPENSATION AS A NEW OUTCOME AND PROGNOSTIC INDICATOR IN CIRRHOTIC PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH ATEZOLIZUMAB PLUS BEVACIZUMAB: A REAL-LIFE MULTICENTER STUDY

Penser à espacer l’ustekinumab de 8 à 12 semaines quand tout va bien ! Monique Devillers (Rotterdam) - LENGTHENING USTEKINUMAB DOSING INTERVALS FROM EVERY 8 WEEKS TO EVERY 12 WEEKS IN IBD PATIENTS IN REMISSION: PRELIMINARY RESULTS OF A PROSPECTIVE OBSERVATIONAL COHORT STUDY

Résection iléo-caecale dans la maladie de Crohn : réfléchir avant de couper ? Nathan Grellier (Poitiers) - MP267- FUNCTIONAL OUTCOMES AFTER PRIMARY ILEOCECAL RESECTION FOR CROHN’S DISEASE

Transplantation fécale : un nouvel outil pour les patients sous immunothérapie ? L’exemple dans le cancer du rein Gianluca Ianiro (Italy) - TARGETED FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS RECEIVING PEMBROLIZUMAB PLUS AXITINIB FOR METASTATIC RENAL CELL CARCINOMA: PRELIMINARY RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TACITO TRIAL)

Pour une meilleure prise en charge des toxicités intestinales liées à l’immunothérapie William Fusco (Italie) - OP096 THERAPEUTIC MODULATION OF GUT MICROBIOME TO TREAT IMMUNE-CHECKPOINT INHIBITORS-RELATED DIARRHEA AND COLITIS: EXPERIENCE OF A MICROBIOME CLINIC

Les statines ont-elles leur places en association aux traitements spécifiques des MICI ? Anders Forss (Suède) - LB05 STATIN USE IS ASSOCIATED WITH A LESS SEVERE DISEASE COURSE IN INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION-BASED COHORT STUDY 2006-2020

Pancréatite aiguë nécrosante : chez qui faire le ménage ? Silvia Bosso (Italy) - MP028 NEED OF ENDOSCOPIC NECROSECTOMY IN WALLED-OFF PANCREATIC NECROSIS TREATED WITH LAMS: A PROSPECTIVE VALIDATION OF A PREDICTIVE CLINICAL INDEX

Un espoir dans la pancréatite chronique ? Tünde Molnár (Hongrie) - OP015 INHIBITION OF PLASMINOGEN ACTIVATOR INHIBITOR-1: A PROMISING NEW APPROACH FOR THE TREATMENT OF CHRONIC PANCREATITIS

La chasse aux lésions digestives hautes est ouverte ! Andreas V Hadjinicolaou (United Kingdom) - OP038 ENDOSCOPIC RECOGNITION OF PREMALIGNANT GASTRIC CONDITIONS IN GENERAL ENDOSCOPY PRACTICE IS LOW: DATA FROM A PROSPECTIVE MULTICENTRE COHORT STUDY (PROSPERO)

Le Cryoballon : la nouvelle arme destructrice de l’EBO Koen Munters (Pays-Bas) - OP116 EFFICACY AND SAFETY OF CRYOBALLOON180 ABLATION FOR THE TREATMENT OF DYSPLASTIC BARRETT ESOPHAGUS: PRELIMINARY RESULTS FROM A PROSPECTIVE MULTICENTER STUDY

Vers une simplification de l’antibiothérapie pour le traitement de l’infection à Helicobacter pylori grâce au Vonoprazan ? Ka Shing Cheung (China) - OP010 VONOPRAZAN-DUAL AND TRIPLE THERAPIES WERE NON-INFERIOR TO BISMUTH-BASED QUADRUPLE THERAPY AS FIRST-LINE THERAPY FOR HELICOBACTER PYLORI INFECTION IN CHINA: A THREE-ARM, RANDOMIZED CLINICAL TRIAL

Une bouffée d’oxygénothérapie hyperbare dans les LAP réfractaires ? Lieven Gerrard Michiel Mulders (Amsterdam, Netherlands) - MP117- HYPERBARIC OXYGEN THERAPY FOR SURGICAL FISTULA CLOSURE IS FEASIBLE IN PERIANAL FISTULIZING CROHN’S DISEASE